This Article Free Full Text (Free PDF) Free References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Seeger, H. Articles by Mueck, A. O Search for Related Content PubMed PubMed Citation Articles by Seeger, H. Articles by Mueck, A. O Social Bookmarking                         What's this?

Valsartan and candesartan can inhibit deteriorating effects of angiotensin II on coronary endothelial function

Section of Endocrinology and Menopause, Department of Obstetrics and Gynaecology, University of Tuebingen, Tuebingen, Germany

Caroline Lippert

Section of Endocrinology and Menopause, Department of Obstetrics and Gynaecology, University of Tuebingen, Tuebingen, Germany

Diethelm Wallwiener

Section of Endocrinology and Menopause, Department of Obstetrics and Gynaecology, University of Tuebingen, Tuebingen, Germany

Alfred O Mueck

Section of Endocrinology and Menopause, Department of Obstetrics and Gynaecology, University of Tuebingen, Tuebingen, Germany, endo.meno@ med.uni-tuebingen.de

The angiotensin II (Ang II) AT₁-receptor antagonists, valsartan and candesartan, were compared with regard to their effect on Ang II-mediated changes in parameters of coronary endothelial function. Ang II (10 µM) induced increased concentrations of the vasoconstrictor endothelin, the procoagulatory substance plasminogen-activator-inhibitor-1 (PAI-1) and the precursor of the matrix-metalloproteinase 1 (MMP-1) in endothelial cell cultures from human coronary arteries. These increases were completely prevented by the addition of 10 µM valsartan or candesartan and partially by the addition of lower concentrations of these drugs, i.e. 1 µM and 0.1 µM. No significant difference between the effect of the two AT₁-receptor antagonists was observed.

These results suggest that AT₁-receptor antagonists not only can reduce blood pressure by blocking the action of Ang II, but might also contribute to the prevention of atherogenesis and plaque instability.

Key Words: valsartan • candesartan • angiotensin II • coronary endothelial function

Journal of Renin-Angiotensin-Aldosterone System, Vol. 2, No. 2, 141-143 (2001)
DOI: 10.3317/jraas.2001.016


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				G. E. Striker, F. Praddaude, O. Alcazar, S. W. Cousins, and M. E. Marin-Castano Regulation of angiotensin II receptors and extracellular matrix turnover in human retinal pigment epithelium: role of angiotensin II Am J Physiol Cell Physiol, December 1, 2008; 295(6): C1633 - C1646. [Abstract] [Full Text] [PDF]

				K. Alfakih, R. A. Lawrance, A. Maqbool, K. Walters, S. G. Ball, A. J. Balmforth, and A. S. Hall The clinical significance of a common, functional, X-linked angiotensin II type 2-receptor gene polymorphism (-1332 G/A) in a cohort of 509 families with premature coronary artery disease Eur. Heart J., March 2, 2005; 26(6): 584 - 589. [Abstract] [Full Text] [PDF]

				K. Chen, J. Chen, D. Li, X. Zhang, and J. L. Mehta Angiotensin II Regulation of Collagen Type I Expression in Cardiac Fibroblasts: Modulation by PPAR-{gamma} Ligand Pioglitazone Hypertension, November 1, 2004; 44(5): 655 - 661. [Abstract] [Full Text] [PDF]